REGN
NASDAQRegeneron Pharmaceuticals Inc.
Price$635.35-152.20 (-19.33%)
2026-03-042026-06-05
News · 26 weeks84-67%
2025-12-142026-06-07
Mix3990d
- Other27(69%)
- SEC Filings5(13%)
- Analyst3(8%)
- Earnings2(5%)
- Insider2(5%)
Latest news
25 items- PRRegeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus OutbreakInmazeb® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically for the Orthoebolavirus zairense species, and has been administered to hundreds of patients Maftivimab, the most potent neutralizing antibody in Inmazeb, has shown broad activity in vitro against multiple Ebola species, including Bundibugyo Maftivimab has been recommended to be studied as a monotherapy in the current outbreak TARRYTOWN, N.Y., May 28, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that maftivimab, the most potent neutralizing antibody
- PROtarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing LossTARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an in vivo adeno-associated virus vector-based gene therapy for the treatment of biallelic OTOF variant-associated hearing loss. Otarmeni, formerly known as DB-OTO, previously received Orphan Designation from the EMA. If approved, Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union (EU). The MAA is supported by data from the pivotal CHORD clinical trial, in which 24 parti
- PRREGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law ViolationsRegeneron executives pointed to optimistic outcomes for a study that was revealed to have failed to achieve its primary endpoint only two months later; shares dropped sharply when the results came in.NEW YORK, May 19, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ:REGN) shareholders saw the stock decline more than 10% when the market opened on May 18, 2026 after investors digested the weekend news that Regeneron's Phase 3 melanoma trial of Fianlimab + Libtayo failed to meet its primary endpoint versus Merck's Keytruda (pembrolizumab). Those who lost money on REGN are encouraged to submit their information to SueWallSt. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueW
- ANALYSTRegeneron Pharma downgraded by Citigroup with a new price targetCitigroup downgraded Regeneron Pharma from Buy to Neutral and set a new price target of $700.00
- ANALYSTRegeneron Pharma downgraded by Leerink Partners with a new price targetLeerink Partners downgraded Regeneron Pharma from Outperform to Market Perform and set a new price target of $641.00
- PRRegeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic AreasThe multi-target collaboration combines Regeneron's industry-leading antibody capabilities with Parabilis' novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from Regeneron, consisting of a $50M upfront payment and $75M equity commitment, with up to approximately $2.2B in additional potential milestone payments plus tiered royalties TARRYTOWN, N.Y., May 18, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates based on Parabilis' Helicon™ peptide platform, with a particular focus on Antibody-Helicon™ Conjugat
- PRUPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering FairTARRYTOWN, N.Y. and WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc., and Society for Science (the Society) announced that Hikaru Kuribayashi, 17, of Sapporo, Japan won the $100,000 George D. Yancopoulos Innovator Award at the Regeneron International Science and Engineering Fair 2026 (Regeneron ISEF), the world's largest precollege science and engineering competition. For more information about the top winners and access to visual assets visit our media kit here. Key Takeaways: This year's finalists received more than $7 million in awards based on their projects' creativity, innovation, and depth of scientific inquiry.The top winners were honored at the Pho
- PRNext Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering FairHikaru Kuribayashi, 17, receives $100,000 Top Award for his creation of a simulation program to understand complex folding at the world's largest pre-college STEM competition. TARRYTOWN, N.Y. and WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Society for Science (the Society) announced that Hikaru Kuribayashi, 17, of Sapporo, Japan won the $100,000 George D. Yancopoulos Innovator Award at the Regeneron International Science and Engineering Fair 2026 (Regeneron ISEF), the world's largest precollege science and engineering competition. Key Takeaways: This year's finalists received more than $7 million in awards based on their projects' creat
- PRBiologics Market Momentum Accelerates Across Healthcare, AI, And Global Medical TourismDENVER, May 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) - The biologics sector is rapidly emerging as one of the most closely watched growth stories in healthcare as breakthroughs in immunotherapy, regenerative medicine, cell engineering, and AI-assisted drug development continue reshaping investor sentiment. Unlike traditional pharmaceutical compounds, biologics leverage complex biological systems to target diseases with greater specificity, opening new opportunities in cancer, autoimmune disorders, rare diseases, and regenerative therapies. The investment narrative around biologics has expanded far beyond drug development alone. Today, the sector sits at the intersection of artific
- SECSEC Form 13F-HR filed by Regeneron Pharmaceuticals Inc.13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- PRRegeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive YearsRegeneron also earns spot on Dow Jones Best-in-Class North America Index for six consecutive years Recognition complements the company's recent announcement that it will provide its new gene therapy for a form of genetic hearing loss for free in the United States, reinforcing its commitment to patient access New science-led 2030 responsibility goals reflect Regeneron's commitment to corporate responsibility, from how it innovates to how it operates, for the good of its business and humanity TARRYTOWN, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced it has been named to the Dow Jones Best-in-Class World Index, one of the world's most r
- PRBiotech's Next Wave May Already be in MotionDENVER, May 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com and NeOnc Technology) - The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction, late-stage clinical wins, and platform technologies are converging to reshape both valuations and patient outcomes. From aggressive insider buying ahead of critical data to blockbuster Phase 3 readouts redefining entire therapeutic categories, the market is signaling that the next cycle of winners may already be taking shape. At the center of this narrative sits a lesser-known but increasingly watched name: NeOnc Technologies (NASDAQ:NTHI), a company whose leadership is making a bold, highly vi
- PRDupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 TrialDupixent showed significant and clinically meaningful improvements in both esophageal distensibility as well as disease-related structural changes and inflammation in the esophagus in adult patients with EoE at week 24 compared to placebo, in results presented at DDW These results reinforce the roles of IL-4 and IL-13, two of the key and central drivers of type 2 inflammation, in EoE EoE is a chronic, progressive disease that causes scarring and narrowing of the esophagus, making it difficult to swallow food, with more pronounced damage increasing the risk for severe symptoms TARRYTOWN, N.Y. and PARIS, May 05, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sa
- INSIDERDirector Ryan Arthur F sold $70,524 worth of shares (100 units at $705.24) as part of a pre-agreed trading plan, decreasing direct ownership by 0.57% to 17,503 units (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- SECSEC Form 10-Q filed by Regeneron Pharmaceuticals Inc.10-Q - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- SECRegeneron Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- SECSEC Form DEF 14A filed by Regeneron Pharmaceuticals Inc.DEF 14A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- SECSEC Form DEFA14A filed by Regeneron Pharmaceuticals Inc.DEFA14A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- PRRegeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha), its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S. Regeneron will lower Medicaid prices based on prices in other developed countries; prices for future medicines in the U.S. will be aligned with prices set in that defined group of other countries Praluent® (alirocumab), an important cardiovascular medicine, will be available for direct patient purchase through TrumpRx.gov Regeneron will continue its large investment in domestic R&D and manufacturing capacity TARRYTOWN, N.Y., April 23, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced an
- PROtarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.Approval in severe-to-profound and profound OTOF-related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the primary endpoint, and with longer follow-up, 42% achieved normal hearing that included whispers First FDA-approved example of a gene therapy to restore a neurosensory function to normal levels Otarmeni is Regeneron's first approved genetic medicine, showcasing its ability to advance new therapeutic approaches to address conditions with great unmet medical need TARRYTOWN, N.Y., April 23, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the U.S. Food an
- PRDupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin disease that causes itch and hives that can be debilitating for young children, especially for those whose disease remains uncontrolled CSU marks the fifth disease driven in part by type 2 inflammation for which Dupixent is approved in children younger than 12 years of age TARRYTOWN, N.Y. and PARIS, April 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) f
- PRPress Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticariaSanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Approval for children aged two to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical study programCSU is a chronic skin disease that causes itch and hives that can be debilitating for young children, especially for those whose disease remains uncontrolledCSU marks the fifth disease driven in part by type 2 inflammation for which Dupixent is approved in children younger than 12 years of age Paris and Tarrytown, NY, April 22, 2026. The US Food and Drug Administratio
- PRCemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 TrialAs published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG U.S. regulatory application submitted; cemdisiran could be the first siRNA to be approved for the treatment of gMG Regeneron to host virtual ‘Regeneron Roundtable: gMG & C5 Complement Program' investor event on Wednesday, April 22 at 8:30 a.m. ET TARRYTOWN, N.Y., April 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced detailed positive results from the Phase 3 NIMBLE trial evaluating investigational cemdisiran in adults with generalized myasthenia gravis (gMG) w
- PRRegeneron Announces Investor Conference PresentationsTARRYTOWN, N.Y., April 20, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: • BofA Securities Health Care Conference 2026 at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, May 12, 2026 • Goldman Sachs 47th Annual Global Healthcare Conference at 2:00 p.m. ET on Monday, June 8, 2026 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days. About Regeneron Regeneron (NASDAQ:REGN) is a leading biotechnology company that invents, devel
- PRRegeneron and Telix Announce Strategic Radiopharma CollaborationRegeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model Collaboration combines Regeneron's leading antibody discovery/development platforms and oncology experience with Telix's expertise in radiopharmaceutical development and manufacturing Telix to receive $40 million USD upfront for four initial programs with optionality to co-fund commercialization and profit-share, or earn up to an aggregate of $2.1 billion USD in development and commercial milestone payments plus low double-digit royalties TARRYTOWN, N.Y. and INDIANAPOLIS and MELBOURNE, Australia, April 13, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharm
REGN FAQ
7 questionsWhat does Regeneron Pharmaceuticals Inc. do?
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults...Where does REGN stock trade?
Regeneron Pharmaceuticals Inc. (REGN) is listed on NASDAQ.What sector and industry is REGN in?
Regeneron Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Regeneron Pharmaceuticals Inc. go public?
Regeneron Pharmaceuticals Inc. (REGN) completed its IPO in 1991.What are analysts saying about REGN?
Regeneron Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Neutral on 2026-05-18.What companies are similar to REGN?
Notable peers in the same industry include ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), SNY (Sanofi). Compare REGN side-by-side with any of them on Quantisnow.How can I track REGN on Quantisnow?
Quantisnow aggregates Regeneron Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow REGN to receive live email and push alerts on every new disclosure.